Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: A comprehensive review

Autoimmun Rev. 2024 Feb;23(2):103499. doi: 10.1016/j.autrev.2023.103499. Epub 2023 Dec 5.

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is a rare central nervous system autoimmune disease. Aquaporin-4 antibody (AQP4-IgG) is present in over 75% of cases and criteria also exist for the diagnosis of seronegative NMOSD. AQP4-IgG NMOSD has a strong female predominance (9:1 ratio), with a median onset age of 40 years. Pregnancy in those with NMOSD is therefore an important topic. Fecundity in NMOSD is likely impaired, and for females who conceive, obstetric complications including miscarriages and pre-eclampsia are significantly higher in NMOSD compared to the general population and in related conditions such as multiple sclerosis (MS). In contrast to MS, NMOSD disease activity does not subside during pregnancy. Also, relapse risk substantially rises above pre-pregnancy rates in the early postpartum period. In view of the evolving landscape of NMOSD, we provide a contemporary update of the impacts of pregnancy in NMOSD.

Keywords: Foetal outcomes; Maternal risks; NMOSD; Obstetrics; Pregnancy; Relapses.

Publication types

  • Review

MeSH terms

  • Aquaporin 4 / immunology
  • Autoantibodies / blood
  • Autoantibodies / immunology
  • Female
  • Humans
  • Neuromyelitis Optica* / diagnosis
  • Neuromyelitis Optica* / epidemiology
  • Neuromyelitis Optica* / immunology
  • Pregnancy
  • Pregnancy Complications* / epidemiology
  • Pregnancy Complications* / immunology
  • Pregnancy Outcome*

Substances

  • Autoantibodies
  • Aquaporin 4